Skip to ContentSkip to Navigation
How to find us dr. A.J. van der Wekken


A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses

Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib

Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients

Detection of on-target ALK inhibitor resistance mutations and treatment options for patients with non-small cell lung cancer

Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

Read more


Actionabiliteit van on-target ALK-resistentiemutaties in niet-kleincellig longcarcinoom

Plasma testing

Longkanker in Perspectief

Oncologie longkanker special

Magazine Longkanker

NOS journaal

RTV noord journaal

Read more